Apogee Therapeutics, Inc.
APGEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeApogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary. With a market capitalization of $10.22B, it sits in large-cap territory. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
Market Cap
$10.22B
Beta
0.34
P/E (TTM)
—
P/E (Fwd)
-25.91
EPS (TTM)
$-4.34
EPS (Fwd)
$-5.21
ROE
-32.5%
ROA
-20.3%
Cash
$971.9M
Total Debt
$6.8M
Free CF
-$145.6M
52W Change
256.7%
Annual Financials
Cash vs Debt
Where APGE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, APGE finished 38.15% above its 150-day moving average ($97.77) and 46.86% above its 200-day moving average ($91.97). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APGE overbought or oversold?
At the September 3, 2026 close, APGE's RSI(14) was 95.6, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $971.9M in cash comfortably exceeding the $6.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$145.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -32.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
APGE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing APGE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.